Attention-Deficit/Hyperactivity Disorder (ADHD) in Female Patients

Kimberly T. Krohn, MD, MPH
Program Director
UND Center for Family Medicine
Associate Professor of Family and Community Medicine, University of North Dakota School of Medicine and Health Sciences

Disclosures

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest. If conflicts are identified, they are resolved prior to confirmation of participation. Only participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.

All faculty and staff in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.

This CME activity is funded by an educational grant to the AAFP from Merck.

 Disclosure of Unlabeled/Investigational Uses of Products

The following faculty have returned forms declaring that the content of their presentation(s) at this AAFP sponsored CME course will include discussion of unapproved or investigational uses of products or devices.

- Various non-stimulant medications including antidepressants.
- Combinations of stimulants with non-stimulants.
- Herbal and OTC products.
- Non-medication interventions.

Objectives

- List the DSM-5 criteria for diagnosing ADHD with emphasis on female patients.
- Describe new developments in understanding etiology of ADHD and implications for care specific to females.
- Describe best evidence interventions and prognosis for ADHD in girls and women.

Pre-Assessment

Please complete your answers on the sheet provided in your syllabus.

Pre-Assessment Question #1

Girls with ADHD are more likely than boys to exhibit which of the following?

A. Butting into conversations, games, or activities
B. Blurting out an answer before the question is completed
C. Running or climbing in inappropriate situations
D. Easily distracted by extraneous stimuli
Pre-Assessment Question #2
Which of the following is true regarding treatment of ADHD in female patients compared to their male counterparts?
A. Female patients are less likely to respond to methylphenidate.
B. Female patients are more likely to require the addition of an antidepressant.
C. Female patients are more likely to respond to an SSRI than an SNRI antidepressant.
D. Pregnancy is an important contraindication to ADHD treatment with most available medications.

Pre-Assessment Question #3
Which of the following is true regarding prognosis in female vs. male patients with ADHD?
A. Female patients are more likely to be diagnosed early due to their tendency to “act out.”
B. Female patients are more likely to “outgrow” their symptoms than male patients.
C. Female patients are more likely to “suffer in silence” than male patients.
D. Girls are less likely to have intellectual impairments along with their ADHD than boys.

SORT
(Strength-of-Recommendation Taxonomy)
A. Consistent, good-quality, patient-oriented evidence
B. Inconsistent, limited-quality, patient-oriented evidence
C. Consensus, disease-oriented evidence, usual practice, expert opinion, or case series

Case: Stacy
CC: 27 yo woman who presents wondering if she has ADHD. She took an online inventory that suggested she has it after she noted similarities with her 7yo son who was diagnosed several months ago and has been doing much better since he started methylphenidate.

Stacy’s HPI
No “special ed” but struggled in school, especially once she started middle school. Dropped out of high school. Was often in trouble due to being late for class or talking. Remembers coming home in tears from being called “Spacy Stacy” by the other kids. Prescribed fluoxetine (Prozac) for depression but quit taking it because she didn’t think it did anything for her.

Stacy’s Additional History
PMH: no meds or medical problems
FSH: Single mom of one child. Difficulty maintaining entry-level jobs; reprimanded at current job due to tardiness when she lost her car keys. Smokes 1 ppd. “Recovering alcoholic and doper, sober for 4 yrs.”
ROS: Depression screen showed sleep latency difficulty and erratic eating, but otherwise negative.
Stacy’s Physical Exam

**Vital Signs**: normal

**General**: Overweight, multiple tattoos, talkative, occasionally interruptive, good eye contact

**Other exam normal**: specifically no thyroid abnormality or heart murmur

**Stacy’s Lab/Assessment**

Urine drug screen negative

**Does Stacy have ADHD?**

**DSM-5 Definition**

**Mental Disorder:**

– **Syndrome**: pattern of psychological, biological, or developmental dysfunction

– **Outcome**: significant distress or disability in social, occupational, or other important activities

– **Individual dysfunction**: not just cultural or social differences

**DSM-5 Presentation Specifiers** (not “types”)

• Attention-Deficit/Hyperactivity Disorder, Combined Presentation

• Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Presentation

• Attention-Deficit/Hyperactivity Disorder, Predominantly Hyperactive-Impulsive Presentation

• (Other Specified ADHD; Unspecified ADHD)

**DSM-5 vs. DSM-IV**

**RE: ADHD**

• “Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence” category removed

• ADHD grouped with “Neurodevelopmental Disorders”

• ADHD not grouped with “Disruptive, Impulse-Control, and Conduct Disorders”

**Etiology: ADHD is a Neurodevelopmental Disorder**

• Strong inheritance evidence (A)

• Growing chromosomal/DNA evidence (B)

• Strong neurochemical evidence related to dopamine and norepinephrine pathways (A)

• Growing neuroanatomic evidence: prefrontal cortex and its connections (B)

• Growing environmental evidence (A,B)
Heritability Comparisons

<table>
<thead>
<tr>
<th>Condition</th>
<th>Monozygotic Twin Concordance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood type</td>
<td>100</td>
</tr>
<tr>
<td>Height</td>
<td>93</td>
</tr>
<tr>
<td>Weight</td>
<td>92</td>
</tr>
<tr>
<td>Eye color</td>
<td>80</td>
</tr>
<tr>
<td>Childhood asthma</td>
<td>65</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>60</td>
</tr>
<tr>
<td>Autism</td>
<td>50</td>
</tr>
<tr>
<td>Diabetes, type 2</td>
<td>50</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>46</td>
</tr>
</tbody>
</table>

Environmental Factors Associated With ADHD

- Maternal smoking
- Fetal exposure to alcohol
- Pregnancy and delivery complications
- Psychosocial adversity
- Exposure to environmental toxins such as PCBs or pesticides
- (NOT TV viewing)
- (A, B)

Syndrome Features

- Inattention
- Hyperactivity/Impulsivity
- Onset before age 12 (7 in DSM-IV)
- Impairment in at least 2 settings (school, work, home)
- Significantly impaired function (specify mild, moderate, severe)
- Not exclusively due to/better explained by another psychiatric disorder

Inattention

6 of these 9 (5 of 9 for ≥ 17 yo): “Often…”
- Fails to give close attention to details
- Difficulty sustaining attention
- Doesn’t seem to listen
- Doesn’t follow through
- Difficulty organizing
- Avoids mental effort
- Loses things
- Easily distracted
- Forgetful in daily activities

Hyperactivity/Impulsivity

6 of these 9 (5 of 9 for ≥ 17 yo): “Often…”
- Fidgets
- Leaves seat
- Runs about or climbs excessively
- Difficulty playing quietly
- “On the go,” “Driven by a motor”
- Talks excessively
- Blurs answers before end of questions
- Difficulty awaiting turn/waiting in line
- Interrupts or intrudes on others

Prevalence

- 5% of school-age children in most cultures (2.5% of adults) per DSM-5 (1.7-17.8% reported)
- Males:females = 2:1 (true vs. false prevalence difference)
Evidence-Based (EB) Recommendation #1 (Diagnosis)

- Evaluate children/adolescents suspected of having ADHD based on (DSM-5) diagnostic criteria using consistent and appropriate diagnostic tools.
  (evidence classes: C, R)

EB Recommendation #2 (Diagnosis)

Screen all patients for other primary conditions or comorbidities and appropriately refer to subspecialty consultation for further evaluation.

Comorbid Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Prevalence in ADHD</th>
<th>Prevalence in General Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conduct disorder</td>
<td>35-45%</td>
<td>3-4%</td>
</tr>
<tr>
<td>Oppositional defiant disorder</td>
<td>45-55%</td>
<td>4-5%</td>
</tr>
<tr>
<td>Depressive disorders</td>
<td>25-30%</td>
<td>4-5%</td>
</tr>
<tr>
<td>Bipolar I disorder</td>
<td>6-10%</td>
<td>1%</td>
</tr>
<tr>
<td>Anxiety disorder</td>
<td>25-35%</td>
<td>8-12%</td>
</tr>
<tr>
<td>Learning disorder</td>
<td>12-30%</td>
<td>5-7%</td>
</tr>
<tr>
<td>Tourette's disorder</td>
<td>0.1%</td>
<td>.05-.1%</td>
</tr>
</tbody>
</table>

Differential Diagnosis

- Cognitive Problem: intellectual disability, learning disability*, autistic disorders
- Medical Problem: allergies, sleep disorders*, lead toxicity, fragile X**
- Neurological Problem: seizure disorder, Tourette’s
- Psychological Problem: depression*, bipolar*, conduct disorder, drug abuse, adjustment disorder
- Family/Social Problem: chaotic or abusive environment*, parental substance abuse

This document may not be copied or shared without prior written consent of the AAFP.
**Evaluation: History Sources**
- Child/Patient
- All Parents (Spouse)
- School Teachers, Counselor, Nurse
- Coaches, Scout Leaders, Coworkers, Others

**Evaluation: History Content**
- Detailed medical, developmental, neurologic, family, sleep, and school history
- Specific examples of problem behaviors
- School evaluations, report cards, achievement tests, class work

**Evaluation: Physical Exam**
- General Medical
- Detailed Neurologic
- Detailed Developmental for Age (verbal and math skills, backward alphabet)
- Height, weight, blood pressure before starting meds

**Evaluation: Lab Tests**
- Hearing and vision screen
- Consider CBC or ferritin
- Consider TSH
- Consider lead level
- EEG if H&P suspicious for seizure
- EKG before stimulants or tricyclics
- Drug screen in teens and adults
- Pregnancy test

**Evaluation: Standardized Questionnaires**
- Conners’ Rating Scales-Revised
  - Teacher and Parent versions
  - Short and Long versions
- Barkley’s Home Situations and School Situations Questionnaires
- ACTers, NICHQ Vanderbilt Assessment Scale, Achenbach, others

**Stacy’s Evaluation**
- Barkley adult symptom checklists for childhood and current symptoms to Stacy, her mom and aunt
- Barkley adult checklist for current symptoms to coworker/friend and to aunt
- Lead, thyroid, iron, vitamin D screens (?)
- EKG (?)
- Continuous Performance Testing in office (?)
Stacy’s Assessment

- ADHD, inattentive presentation, adult, moderate
- Smoking
- History of multi-drug abuse, not active

How would you treat her?

EB Recommendation #3 (Treatment)

Establish appropriate use of medication in both initial and ongoing management of patients with ADHD.

(evidence classes: A, C, R)

EB Recommendation #4 (Treatment)

ADHD is rarely a singular diagnosis. Multimodal intervention is commonly needed for other concomitant conditions and comorbidities (special ed, mental health, etc.).

(evidence classes: A, C, M)

EB Recommendation #5 (Treatment)

Provide consistent and comprehensive monitoring and care coordination for all patients with ADHD including pharmacologic and non-pharmacologic interventions, identification and management of emerging comorbidities, and the impact of ADHD condition on patients, their families, and schools.

(evidence classes: A, C, D, M, R)

Family/Social Consequences to Address

- Family/classroom chaos
- Parental guilt/comorbidity
- Ineffective discipline; abuse
- Social isolation
- Academic underachievement
- Dangerous impulses

Behavior Management

Psychotherapy
- Children: Behavior training for parents/teachers (A), insight therapy/support groups for parents/teachers (C)
- Teens/adults: Cognitive behavioral therapy (A), coaching (B), insight therapy/support groups (C)

Environmental/educational modification
- Classroom accommodations vs. special education interventions (B,C)
- Remove distractions (C)
- Supervise closely/parent-teacher communication (C)
- Individualized sports (C)
Medications

- Stimulants
- Atomoxetine
- Antidepressants
- Alpha-2 agonists
- Others

Stimulants

- Methylphenidates
  - Methylphenidate: Concerta, Daytrana, Metadate, Methylin, Quillivant, Ritalin
  - Dexmethylphenidate: Focalin, generic
- Amphetamines
  - Dextroamphetamine: Dexedrine, ProCentra
  - Amphetamine mixture: Adderall
  - Lisdexamfetamine: Vyvanse

Stimulant Effects

- Motor activity decreases
- Certain cognitive processes improve
- Motivation improves
- Academic performance improves
- Oppositional and aggressive behaviors decrease (A)

Common Methylphenidate Side Effects

<table>
<thead>
<tr>
<th></th>
<th>Odds Ratio vs. Placebo</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5.29</td>
<td>2.51-11.15</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7.50</td>
<td>1.93-29.13</td>
</tr>
<tr>
<td>Stomachache</td>
<td>7.0</td>
<td>3.29-14.89</td>
</tr>
<tr>
<td>Appetite loss</td>
<td>19.0</td>
<td>9.18-39.31</td>
</tr>
<tr>
<td>Insomnia</td>
<td>3.1</td>
<td>1.80-5.42</td>
</tr>
</tbody>
</table>

Other Stimulant Side Effects

- Less common: depression, irritability, rebound problems
- Infrequent: tics, OCD, palpitations
- Rare: "Zombie effect," growth suppression, psychosis, seizures, sudden death

Stimulants and Sudden Death

- Screen for cardiac risk with standard pre-participation sports exam questions:
  - Spontaneous syncope
  - Exercise-induced syncope
  - Exercise-induced chest pain/discomfort
  - Sudden death in family member <30yo
  - Fam hx of cardiac abnormality (structural or electrical)
- Further evaluation of +’s
- Document risk discussion
Ritalin Diversion/Abuse

<table>
<thead>
<tr>
<th></th>
<th>2001</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>12th Grader Prevalence, non-medicinal/illicit use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritalin</td>
<td>5.1</td>
<td>2.3</td>
</tr>
<tr>
<td>Been drunk, alcohol</td>
<td>53.2</td>
<td>43.5</td>
</tr>
<tr>
<td>Marijuana</td>
<td>37.0</td>
<td>36.4</td>
</tr>
<tr>
<td>Cocaine</td>
<td>4.8</td>
<td>2.6</td>
</tr>
<tr>
<td>Steroids</td>
<td>2.4</td>
<td>1.5</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.9</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Monitoring the Future study, University of Michigan [www.monitoringthefuture.org] as of 8-29-14.

Pearls for Stimulant Administration

- First line in patients of all ages and both genders unless there is a specific contraindication
- Use caution < 6 yo or > 12 yo
- Give enough, often enough
- Measure benefit
- Follow up at least every 3-6 months
- Consider annual discontinuation
- Keep good prescription records

Atomoxetine (Strattera®)

- Appears safe and effective
- Once daily dosing, usually
- Convenient (not DEA Schedule II)
- Full effect may take 4 weeks
- Second line at present

Prescriber’s Letter Detail Document #220214. 2006 (B)

Atomoxetine vs. Methylphenidate

<table>
<thead>
<tr>
<th></th>
<th>Atomoxetine (N=222)</th>
<th>Osmotic-Release Methylphenidate (N=220)</th>
<th>Placebo (N=74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response rate</td>
<td>45%*</td>
<td>56%**</td>
<td>24%</td>
</tr>
<tr>
<td>Response rate in primary failures</td>
<td>43%</td>
<td>42%</td>
<td></td>
</tr>
<tr>
<td>Side effects &gt; placebo:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>14%</td>
<td>17%</td>
<td>3%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>6%</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>1%</td>
<td>1%</td>
<td>1%</td>
</tr>
</tbody>
</table>

Sources 9, 10 Listed in back of handout CME
Antidepressants Effective for ADHD

- TCAs
  - Imipramine (Tofranil, generic)
  - Desipramine (Norpramin, generic)
  - Nortriptyline (Pamelor, generic)
- Bupropion* (Wellbutrin, generic)
- SNRIs
  - Venlafaxine (Effexor®, generic)
  - Duloxetine (Cymbalta, generic)
- (SSRIs not effective)
- (A,B) *FDA-approved for ADHD

Antidepressants vs. Stimulants

- Advantages
  - No abuse potential
  - Mood stabilizers
  - No appetite loss
- Disadvantages
  - Cardiac toxicity, seizures
  - Less dependable ADHD treatment
- (A, B)

Alpha-2 Agonists

- Clonidine (Kapvay, Catapres) and Guanfacine (Intuniv)
- Mostly behavioral effect rather than cognition
- Adjuncts to stimulants for hyperactive and oppositional symptoms
- Useful for ADHD + Tics or ADHD with insomnia
- Side effects: hypotension, rebound hypertension, sedation (give at night), headache, depression
- (A,B)

ADHD Meds in Pregnancy/Lactation

<table>
<thead>
<tr>
<th>Medication</th>
<th>Pregnancy Risk</th>
<th>Lactation Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate, Dexamethylphenidate</td>
<td>C</td>
<td>Probably safe</td>
</tr>
<tr>
<td>Dextroamphetamine, Mixed Amphetamines</td>
<td>C</td>
<td>Safety conditional</td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>C</td>
<td>Safety unknown</td>
</tr>
<tr>
<td>Bupropion</td>
<td>C</td>
<td>Possibly unsafe</td>
</tr>
<tr>
<td>Desipramine</td>
<td>C</td>
<td>Safety unknown</td>
</tr>
<tr>
<td>Imipramine, Nortriptyline</td>
<td>D</td>
<td>Probably safe</td>
</tr>
<tr>
<td>Duloxetine, Venlafaxine</td>
<td>C</td>
<td>Safety unknown</td>
</tr>
<tr>
<td>Clonidine</td>
<td>C</td>
<td>Safety unknown</td>
</tr>
<tr>
<td>Guanfacine</td>
<td>B</td>
<td>Safety unknown</td>
</tr>
</tbody>
</table>

Source: ePocrates

Non-Prescription Remedies

- Caffeine: mild stimulant, helps some but with greater side effects than other stimulants
- Herbal remedies: unproven in children, lack consistency, cause potential harm
- Sugar restriction: no benefit, no harm
- Few foods diet: no benefit, potential harm
- Cognitive training: possible benefit may not be sustained

Stacy's Plan: Which Medication to Start?

- Long-acting methylphenidate (Concerta), 18-36 mg q AM, vs.
- Lisdexamfetamine (Vyvanse) 30 mg q AM, vs.
- Atomoxetine (Strattera), 40 mg q AM x3 then 80 mg q AM, vs.
- Bupropion (Wellbutrin) 100 mg q AM x7 then 200 mg q AM

F/U every few weeks with titration of meds to effectiveness (define means to measure), or side-effects, or maximum FDA-approved dose.
Stacy’s Plan:  
Behavioral/Ancillary Interventions

- Coaching/observation agreement with girlfriend and aunt
- Reading assignments
  - [www.ncgiadd.org](http://www.ncgiadd.org), resources from Dr. P Quinn
  - *ADD-Friendly Ways to Organize Your Life*, Kolberg & Nadeau
- Offer counseling for her, parenting skills, family as necessary
- Smoking cessation

When to Refer

- Uncertain diagnosis
- Not responding to treatment
- Complication of treatment or of disorder

Pearls for ADHD Diagnosis in Females

- Harder to recognize than in males due to higher incidence of inattentive presentation alone and lack of acting out
- Delayed diagnosis common:
  - Often diagnosed with depression before ADHD
  - Bring it up with parents of ADHD children
- Girls have greater intellectual impairments and more internalizing problems than boys
- Use standardized questionnaires with age/gender norms
  - (B,C)

Pearls for ADHD Treatment in Females

- As with males, stimulants are first line
- Stimulant dose may need to be lowered at menarche and peri-menopause
- Non-stimulants appropriate as alternatives and adjuncts, especially in comorbid situations
- Keep potential pregnancy in mind

Pearls for ADHD Prognosis in Females

- Girls and women more likely to suffer in silence due to personal and community lack of awareness
- May or may not have worse problems with self-esteem
- Rates of symptom continuation/impairment in adolescence and adulthood similar to males (about 2/3)

Post-Assessment

Please complete your answers on the sheet provided in your syllabus.

**Note:** The questions are not in the same order as the pre-assessment.
Post-Assessment Question #1
Which of the following is true regarding treatment of ADHD in female patients compared to their male counterparts?
A. Female patients are less likely to respond to methylphenidate.
B. Female patients are more likely to require the addition of an antidepressant.
C. Female patients are more likely to respond to an SSRI than an SNRI antidepressant.
D. Pregnancy is an important contraindication to ADHD treatment with most available medications.

Post-Assessment Question #2
Which of the following is true regarding prognosis in female vs. male patients with ADHD?
A. Female patients are more likely to be diagnosed early due to their tendency to “act out.”
B. Female patients are more likely to “outgrow” their symptoms than male patients.
C. Female patients are more likely to “suffer in silence” than male patients.
D. Girls are less likely to have intellectual impairments along with their ADHD than boys.

Post-Assessment Question #3
Girls with ADHD are more likely than boys to exhibit which of the following?
A. Butting into conversations, games, or activities
B. Blurtling out an answer before the question is completed
C. Running or climbing in inappropriate situations
D. Easily distracted by extraneous stimuli

Resources/References
• DSM-5 ([www.dsm5.org](http://www.dsm5.org))
• CHADD: Children and Adults With ADHD ([www.chadd.org](http://www.chadd.org))
• ADD WareHouse 1-800-233-9273 ([www.addwarehouse.com](http://www.addwarehouse.com))
• Am Acad Pediatrics NICHQ ADHD toolkit ([http://www.nichq.org/childrens-health/adhd/resources](http://www.nichq.org/childrens-health/adhd/resources))
• ICSI Health Care Guideline on ADHD ([www.icsi.org](http://www.icsi.org))
• MyADHD ([www.MyADHD.com](http://www.MyADHD.com))

Presentation Sources Listed in the Back of the Handout
Sources

1. Strength-of-Recommendation Taxonomy (SORT) from American Family Physician, accessed 8-26-14
2. DSM-5, Am Psychiatric Assoc, 2013
4. ICSI Guideline: Diagnosis and Management of ADHD. March 2012 (www.icsi.org)

Sources-con’t